Patents by Inventor Jennifer Maynard

Jennifer Maynard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered coronavirus spike (s) protein and methods of use thereof
    Patent number: 12617820
    Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: May 5, 2026
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jason McLellan, Jennifer Maynard, Andrea Chasse, Ilya Finkelstein, Mohammad Javanmardi, Jeffrey Schaub, Hung-Che Kuo, Chia-Wei Chou, Jory Goldsmith, Christy Hjorth, Ching-Lin Hsieh, Patrick Byrne, Nicole Johnson, Nianshuang Wang, Daniel Wrapp
  • PH-SELECTIVE ANTIBODY FC DOMAINS
    Publication number: 20250188186
    Abstract: Recombinant polypeptides are provided that comprise pH-selective mammalian IgG1 Fc domains that selectively binds to Fc?RIIIa in an acidic environment. The pH-selective mammalian IgG1 Fc domain has reduced affinity for Fc?RIIIa at neutral pH as compared to a wild-type mammalian IgG1 Fc domain while having equivalent affinity for Fc?RIIIa at pH 6.5 as compared to a wild-type mammalian IgG1 Fc domain. Also provided are recombinant polypeptides comprising the pH-selective mammalian IgG1 Fc domains as well as methods of making and using such recombinant polypeptides.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 12, 2025
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer MAYNARD, Yutong LIU, Annalee NGUYEN
  • ENGINEERED FC DOMAINS AND ENGINEERED HCMV VIRAL FC RECEPTORS
    Publication number: 20250127885
    Abstract: Recombinant antibodies are provided that comprise engineered human IgG1 Fc domains that have reduced affinity for viral Fc?Rs, such as HCMV gp34 and gp68, as compared to a wild-type human IgG1 Fc domain. The engineered human IgG1 Fc domains have equivalent affinity for CD16A and FcRn as compared to a wild-type human IgG1 Fc domain. Also provided are engineered forms of HCMV gp34 and their use in a vaccine.
    Type: Application
    Filed: December 9, 2022
    Publication date: April 24, 2025
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer MAYNARD, Ahlam QERQEZ, Alison G. LEE, Sumit PAREEK
  • CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN
    Publication number: 20240294611
    Abstract: Provided herein are antibodies and antibody fragments that bind to the S2 domains of SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins. Methods of using these antibodies in in vitro methods are provided. Methods of using these antibodies in vivo to treat or prevent SARS-CoV-2 infections are also provided.
    Type: Application
    Filed: January 11, 2022
    Publication date: September 5, 2024
    Inventors: Jennifer MAYNARD, Yimin HUANG, Annalee NGUYEN, Ching-Lin HSIEH, Jason MCLELLAN, Rui P. SILVA, Edurado PADLAN
  • ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230242594
    Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jason MCLELLAN, Jennifer MAYNARD, Andrea CHASSE, Ilya FINKELSTEIN, Mohammad JAVANMARDI, Jeffrey SCHAUB, Hung-Che KUO, Chia-Wei CHOU, Jory GOLDSMITH, Christy HJORTH, Ching-Lin HSIEH, Patrick BYRNE, Nicole JOHNSON, Nianshuang WANG, Daniel WRAPP
  • STABILIZED PERTUSSIS ANTIBODIES WITH EXTENDED HALF-LIFE
    Publication number: 20210332112
    Abstract: The present invention relates, in part, to modified humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed, in part, to improved humanized 1B7 and 11E6 antibodies with extended in vivo half-lives.
    Type: Application
    Filed: August 15, 2017
    Publication date: October 28, 2021
    Inventors: Jennifer MAYNARD, Annalee NGUYEN, Michael KALEKO
  • Bispecific pertussis antibodies
    Patent number: 10538579
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: January 21, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Ellen Wagner
  • Humanized pertussis antibodies and used thereof
    Patent number: 10526400
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 7, 2020
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Engineered polypeptides for antigen delivery
    Patent number: 10450352
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 22, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Xianzhe Wang, Tarik Ali Khan
  • ENGINEERED POLYPEPTIDES FOR ANTIGEN DELIVERY
    Publication number: 20190106463
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 11, 2019
    Inventors: Jennifer MAYNARD, Xianzhe WANG, Tarik Ali KHAN
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20180362621
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 20, 2018
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Humanized pertussis antibodies and uses thereof
    Patent number: 10035846
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 31, 2018
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • BISPECIFIC PERTUSSIS ANTIBODIES
    Publication number: 20180118817
    Abstract: The present invention relates, in part, to bispecific antibodies that bind the pertussis toxin protein. The present invention further relates to the use of the bispecific antibodies for the prevention and treatment of Bordetella pertussis infections.
    Type: Application
    Filed: August 15, 2017
    Publication date: May 3, 2018
    Inventors: Jennifer MAYNARD, Ellen WAGNER
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20170066816
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • Humanized pertussis antibodies and uses thereof
    Patent number: 9512204
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: December 6, 2016
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SYNTHETIC BIOLOGICS, INC.
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan, Ellen Wagner
  • HUMANIZED PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20150353628
    Abstract: The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
    Type: Application
    Filed: March 31, 2015
    Publication date: December 10, 2015
    Inventors: Jennifer Maynard, Annalee Nguyen, Eduardo Padlan
  • antibodies and uses thereof
    Patent number: 8653243
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: February 18, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jennifer Maynard, Jamie Sutherland
  • PERTUSSIS ANTIBODIES AND USES THEREOF
    Publication number: 20120244144
    Abstract: Compositions and methods are provided that are useful to treat respiratory diseases such as whooping cough. Further, compositions and methods of immunizing are provided.
    Type: Application
    Filed: September 19, 2011
    Publication date: September 27, 2012
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jennifer Maynard, Jamie Sutherland